ADAM17 (A Disintegrin and Metalloprotease 17), also known as TACE (Tumor Necrosis Factor-α Converting Enzyme), is a membrane-anchored protease.
– It is best known for cleaving and releasing the extracellular domains (ectodomains) of various cell surface proteins, a process called “ectodomain shedding.”
Numerous studies have documented increased ADAM17 expression in several cancers, such as breast, lung, colon, and pancreatic cancers.
– Upregulation often correlates with enhanced release of growth factors (e.g., EGF family ligands) and cytokines that may drive tumor growth and modify the tumor microenvironment.
– Higher levels of ADAM17 have been linked with more aggressive tumor characteristics, including increased invasiveness, metastasis, and resistance to certain therapies.
– In cancers such as breast and lung, elevated ADAM17 expression is often associated with poor clinical prognosis.
(Will delete Record if Target field = "Delete") Home